Affymetrix Announces Redemption of 3.50% Senior Convertible Notes

  Affymetrix Announces Redemption of 3.50% Senior Convertible Notes

Business Wire

SANTA CLARA, Calif. -- December 03, 2012

Affymetrix, Inc., (NASDAQ: AFFX) today has given notice of its intention to
redeem all of the outstanding 3.50% Senior Convertible Notes due 2038 (CUSIP
00826TAG3) (the “Convertible Notes”) on January 15, 2013. As of November 15,
2012, there was approximately $3.9 million aggregate principal amount of the
Convertible Notes outstanding. The Convertible Notes will be redeemed at a
redemption price of 100% of the principal amount of the Convertible Notes
redeemed, plus accrued and unpaid interest up to, but excluding, the
redemption date.

The Convertible Notes are convertible at any time prior to the close of
business on January 14, 2013 at a rate of 33.1991 shares of common stock per
$1,000 principal amount. The Convertible Notes surrendered for conversion will
be settled in cash and stock in accordance with the provisions of the

The Bank of New York Mellon Trust Company, N.A., the trustee for the
Convertible Notes, is distributing a Notice of Redemption to all registered
holders of the Convertible Notes on December 3, 2012. Copies of such Notice of
Redemption and additional information relating to the procedure for redemption
and/or conversion of the Convertible Notes may be obtained from The Bank of
New York Mellon Trust Company, N.A. by calling 1-800-254-2826.

This announcement does not constitute an offer to buy or sell or the
solicitation of an offer to sell or buy securities in any jurisdiction.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic,
and biotechnology companies, as well as leading academic, government, and
nonprofit research institutes. More than 2,200 systems have been shipped
around the world and almost 26,000 peer-reviewed papers have been published
using the technology. Affymetrix is headquartered in Santa Clara, California,
and has manufacturing facilities in Cleveland, Ohio, and Singapore.
eBioscience is headquartered in San Diego, California and has manufacturing
facilities in San Diego and Vienna, Austria. Including eBioscience, the
Company has about 1,200 employees worldwide and maintains sales and
distribution operations across Europe, Asia and Latin America.

Forward-Looking Statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix's "expectations," "beliefs," "hopes," "intentions," "strategies" or
the like. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially for Affymetrix from those projected,
including, but not limited to: Affymetrix's ability to timely and successfully
integrate and realize the anticipated strategic benefits and costs savings or
other synergies of the acquisition of eBioscience in a cost-effective manner
while minimizing the disruption to its business; risks that eBioscience’s
future performance may not be consistent with its historical performance;
risks relating to Affymetrix's ability to make scheduled payments of the
principal of, to pay interest on or to refinance its indebtedness; risks
relating to Affymetrix's ability to successfully develop and commercialize new
products, including its ability to successfully develop and commercialize
novel molecular solutions based on eBioscience’s portfolio of reagents; risks
relating to past and future acquisitions, including the ability of Affymetrix
to successfully integrate such acquisitions into its existing business; risks
of Affymetrix's ability to achieve and sustain higher levels of revenue,
higher gross margins and reduced operating expenses; risks relating to
Affymetrix’s ability to generate cash in the second half of 2012 after
interest and principal payments; uncertainties relating to technological
approaches; risks associated with manufacturing and product development;
personnel retention; uncertainties relating to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties relating to
sole-source suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and other risk
factors are discussed in Affymetrix's Annual Report on Form 10-K for the year
ended December 31, 2011, and other SEC reports. Affymetrix expressly disclaims
any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in
Affymetrix's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.


Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the
property of Affymetrix, Inc.


Affymetrix, Inc.
Doug Farrell, 408-731-5285
Vice President of Investor Relations
Press spacebar to pause and continue. Press esc to stop.